Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1600 participants.
Also called NCT03080935
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,600 participants
- Sponsor
- Registry
-
NCT03080935 -
2016-004066-26
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Belgium, Denmark, France, Germany, Italy, Portugal, Sweden
- Registry status
- Terminated
Technical summary
Registry record NCT03080935. Allocation not applicable; no masking; primary purpose treatment. Start 2017-03-13 (actual); primary completion 2022-03-04 (actual). Results posted on 2023-01-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries
- Condition
- Dyslipidemia
- Intervention (Drug)
- Evolocumab
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct03080935- Content hash
532791421e4531fa0d8e999c1a285677ba9aaa12f88ba66491fb5d7627fdc6c3